Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
(RTTNews) - Prime Medicine, Inc.(PRME), Tuesday announced the initiation of its preclinical program for the treatment of Alpha-1 Antitrypsin Deficiency or AATD using its proprietary Prime Editing ...
(RTTNews) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback